Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $53.38 USD
Change Today -4.74 / -8.16%
Volume 775.3K
PTCT On Other Exchanges
As of 8:10 PM 07/27/15 All times are local (Market data is delayed by at least 15 minutes).

ptc therapeutics inc (PTCT) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/9/15 - $78.72
52 Week Low
08/4/14 - $26.02
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PTC THERAPEUTICS INC (PTCT)

ptc therapeutics inc (PTCT) Related Bloomberg News

View More Bloomberg News

ptc therapeutics inc (PTCT) Details

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The company’s lead product is Translarna (ataluren), which is in Phase III clinical trials for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and for the treatment of cystic fibrosis caused by nonsense mutations. It also intends to develop Translarna for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, as well as develops spinal muscular atrophy, which is in Phase II clinical program. The company’s preclinical development programs include PTC596, a development candidate used for the treatment of chemotherapy resistant cancers; and PTC672, an antibacterial development candidate for the treatment of life-threatening infections caused by multidrug-resistant Gram-negative bacteria. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program. The company was founded in 1998 and is based in South Plainfield, New Jersey.

187 Employees
Last Reported Date: 03/2/15
Founded in 1998

ptc therapeutics inc (PTCT) Top Compensated Officers

Co-Founder, Chief Executive Officer and Execu...
Total Annual Compensation: $495.0K
Chief Commercial Officer
Total Annual Compensation: $368.2K
Chief Medical Officer
Total Annual Compensation: $329.3K
Compensation as of Fiscal Year 2014.

ptc therapeutics inc (PTCT) Key Developments

PTC Therapeutics, Inc. Appoints Glenn D. Steele to Board of Directors

PTC Therapeutics, Inc. announced the appointment of Glenn D. Steele Jr., M.D., Ph.D. to the company's Board of Directors. Dr. Steele served as President and Chief Executive Officer of Geisinger Health from March 2001 until May 2015 and is now Chairman of xG Health Solutions, a Geisinger spinoff. Dr. Steele previously served as the dean of the Biological Sciences Division and the Pritzker School of Medicine and vice president for medical affairs at the University of Chicago, as well as the Richard T. Crane Professor in the Department of Surgery. Prior to that, he was the William V. McDermott Professor of Surgery at Harvard Medical School, President and Chief Executive Officer of Deaconess Professional Practice Group and chairman of the department of surgery at New England Deaconess Hospital in Boston. Dr. Steele serves on the board of directors of several public companies, including, CEPHEID, Weis Markets Inc., and Wellcare Health Plans Inc. In addition, Dr. Steele serves on the governing body of several private organizations, including Bucknell University, xG Health Solutions, and Geisinger Health System.

PTC Therapeutics, Inc. Announces German Federal Joint Committee Issues Positive Medical Benefit Rating for Translarna™ in Patients with Nonsense Mutation Duchenne Muscular Dystrophy

PTC Therapeutics, Inc. announced that the Benefit Assessment by Germany's Federal Joint Committee (G-BA) indicated that Translarna (ataluren) provided a benefit for ambulatory patients aged five years and older with nonsense mutation Duchenne Muscular Dystrophy (nmDMD). The G-BA came to the decision that the existing clinical data package presented by PTC provided convincing evidence for the demonstration of a clinically meaningful added benefit. PTC received a 3 in the rating system established under the German pharmaceutical law.

PTC Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2015

PTC Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenue of $7,482,000 compared to $9,217,000 a year ago. Loss from operations was $38,071,000 compared to $14,212,000 a year ago. Net loss was $37,915,000 compared to $14,098,000 a year ago. Basic and diluted net loss per share was $1.15 compared to $0.58 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PTCT:US $53.38 USD -4.74

PTCT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PTCT.
View Industry Companies

Industry Analysis


Industry Average

Valuation PTCT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 81.7x
Price/Book 7.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 71.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PTC THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at